Advertisement

Advertisement

2023 ASH

Lymphoma

First-Line Treatment for Older Patients With Mantle Cell Lymphoma: Venetoclax Plus Standard Chemoimmunotherapy

The phase II PrE0405 trial met its primary endpoint, achieving a complete response rate of 85% in 33 patients with mantle cell lymphoma over age 60 who received bendamustine and rituximab, a standard ...

lymphoma

Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib

Bijal D. Shah, MD, of Moffitt Cancer Center and Research Institute, discusses a matching-adjusted indirect comparison of brexucabtagene autoleucel and pirtobrutinib in patients with relapsed or refrac...

Leukemia
Issues in Oncology

Understanding Racial and Ethnic Disparities in Modern AML Care After the Approval of Venetoclax

Use of venetoclax may increase survival in non-Hispanic Black patients with acute myeloid leukemia (AML), according to recent findings presented by Wang et al at the 2023 American Society of Hematolog...

Hematologic Malignancies
Issues in Oncology

Bezuclastinib May Reduce Symptoms in Patients With Nonadvanced Systemic Mastocytosis

The targeted therapy bezuclastinib may be safe and effective at reducing markers of disease burden and improving symptoms in patients with nonadvanced systemic mastocytosis, according to recent findin...

Multiple Myeloma
Immunotherapy
Issues in Oncology

Use of Elranatamab for Black Patients With Multiple Myeloma

Elranatamab may be safe and effective in Black patients with relapsed or refractory multiple myeloma, according to new findings presented by Varshavsky-Yanovsky et al at the 2023 American Society of H...

multiple myeloma

Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab

Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple my...

lymphoma

Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib

Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrat...

Leukemia

Revumenib in High-Risk KMT2A-Rearranged Acute Leukemia

Patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2A gene, a genetic marker known as KMT2A, who were treated with revumenib, a small-molecule inhib...

Hematologic Malignancies
Issues in Oncology
Symptom Management

Ruxolitinib Plus Navitoclax May Reduce Spleen Volume in Patients With Myelofibrosis

The Janus kinase (JAK) inhibitor ruxolitinib plus the B-cell lymphoma 2 protein inhibitor navitoclax may be twice as effective at spleen volume reduction compared with standard-of-care ruxolitinib mon...

Hematologic Malignancies
Issues in Oncology

Novel BET Inhibitor for Advanced Myelofibrosis

Researchers may have uncovered a new type of targeted therapy for patients with advanced myelofibrosis, according to new findings presented by Watts et al at the 2023 American Society of Hematology (A...

Leukemia
Genomics/Genetics

Menin Inhibitors in Patients With Advanced AML and Gene Mutations

Two new studies have demonstrated positive results from novel therapies targeting menin for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with specific gene mutati...

Leukemia

Presence of MRD After Chemotherapy May Predict Benefit From Donor Transplant in NPM1-Mutated AML

Among patients who have acute myeloid leukemia (AML) with genetic mutations in NPM1, those with no residual leukemia cells in the blood based on high-sensitivity testing after two cycles of chemothera...

Multiple Myeloma

Daratumumab Plus VRd Outperforms VRd Alone for Multiple Myeloma

Newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) had significantly higher rates of surv...

Myelodysplastic Syndromes
Genomics/Genetics

Potential Underlying Genetic Mutations Identified in Patients With Myelodysplastic Syndromes

Researchers may have uncovered the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes and other myeloid neoplasms, according to new findings presented by ...

Lymphoma

Ibrutinib/Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma

Patients with relapsed or refractory mantle cell lymphoma who received ibrutinib in combination with venetoclax experienced significantly better rates of progression-free survival compared with patien...

Lymphoma
Issues in Oncology

Novel CAR T-Cell Therapy May Show Early Efficacy in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Early results from a new study have demonstrated that the novel chimeric antigen receptor (CAR) T-cell therapy AT101 resulted in favorable complete response rates at higher dose levels in patients wit...

Hematologic Malignancies
Issues in Oncology

AI Model May Help Distinguish Between Two Rare Hematologic Malignancies

A novel artificial intelligence (AI) model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia, according to new findings presented by Srisuwa...

Lymphoma
Immunotherapy

CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins

Data presented at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into r...

Leukemia

Oral Regimen With Minimal Chemotherapy Found to Be Safe, Effective for Patients With APL

Patients with acute promyelocytic leukemia (APL) who received a combination therapy including arsenic trioxide, all-trans retinoic acid, and ascorbic acid (AAA) in oral form with no or minimal chemoth...

Lymphoma

Autologous Stem Cell Transplant vs CAR T-Cell Therapy in Patients With Relapsed LBCL in Complete Remission

For patients with large B-cell lymphoma (LBCL) who have an early relapse or whose cancer doesn’t respond to first-line treatment, randomized trials have shown that chimeric antigen receptor (CAR) T-ce...

Leukemia

Ibrutinib Plus Venetoclax—With Duration of Treatment Determined by MRD—in Newly Diagnosed CLL

Among patients newly diagnosed with chronic lymphocytic leukemia (CLL) who were treated with two targeted agents and whose duration of treatment was determined by high-sensitivity testing for residual...

Leukemia
Issues in Oncology

Psychiatric and Substance Use Disorders May Be Linked to Poorer Outcomes in AML Following Venetoclax Combination Therapies

Researchers have found that patients with psychiatric or substance use disorders may have an increased risk of experiencing poorer outcomes such as early mortality following treatment for acute myeloi...

Multiple Myeloma
Issues in Oncology

Patients With Multiple Myeloma May Experience Poorer Outcomes in the Real World Compared With Reported Outcomes From Clinical Trials

Researchers identified a 75% higher rate of mortality among patients treated for multiple myeloma in real-world hospital settings compared with rates reported in clinical trials involving common thera...

Hematologic Malignancies
Issues in Oncology

Male Researchers Lead the Majority of NIH’s Active R01 Grants in Classical Hematology Research

Investigators have found that in the past decade, a majority of the National Institutes of Health’s (NIH) active R01 grants related to classical, nonmalignant hematology were led by male investigators...

Leukemia
Issues in Oncology

ACS10 Score May Help Inform Treatment, Reduce Racial Disparities in Black Pediatric Patients With AML

Researchers may have uncovered a close link between genetic factors and racial disparities in pediatric patients with acute myeloid leukemia (AML), according to new findings presented by Lamba et al a...

Advertisement

Advertisement




Advertisement